Published in final edited form as:

J Clin Psychiatry. 2011 April ; 72(4): 567–569. doi:10.4088/JCP.10l06653.

Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient with Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report

Carolyn I. Rodriguez, M.D., Ph.D.^{a,b}, Lawrence S. Kegeles, M.D., Ph.D.^{a,b}, Pamela Flood, M.D.^c, and Helen Blair Simpson, M.D., Ph.D.^{a,b}

^aNew York State Psychiatric Institute, New York, NY 10032

^bDepartment of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY 10032

^cDepartment of Anesthesia, Columbia University, College of Physicians and Surgeons, New York, NY 10032

Keywords

Anxiety Disorders; glutamate; obsessive-compulsive disorder; OCD; ketamine; NMDA

To the Editor

Obsessive-compulsive disorder (OCD) is a leading cause of illness-related disability.¹ Identifying more effective treatments with faster onset of action would be a major advance. Medications thought to modulate the glutamate system are promising new agents: for example, open trials of riluzole, memantine, and minocycline as augmentation to serotonin reuptake inhibitors (SRI) suggest that up to half of OCD patients may experience reductions in symptoms.^{2–7} We chose to test intravenous ketamine (a non-competitive N-methyl-D-aspartate [NMDA] receptor antagonist) in an OCD patient for three reasons: 1) it is known to modulate the glutamate system, sharing some mechanistic similarity to memantine;⁸ 2) mice with a genetic deletion in a postsynaptic scaffolding protein (SAPAP3) have OCD-like compulsive behavior thought to be caused by increased NMDA activity and ketamine decreases NMDA activity;⁹ 3) it has been safely used in patients with depression and can relieve depressive symptoms in hours.^{10, 11}

The following case report describes the rapid resolution of obsessions in an OCD patient when she received ketamine in a double-blind cross-over design of intravenous ketamine versus saline. To our knowledge, this is the first report to describe the use of ketamine in an OCD patient.

Corresponding Author: Carolyn Rodriguez, M.D., Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, Unit 69, New York, NY 10032; 212-543-5637 (phone); 212-543-6515 (fax); cr2163@columbia.edu.

Previous Presentation: None

Financial disclosures: Drs. Rodriguez, Kegeles, Flood, and Simpson report no additional financial or other relationships relevant to the subject of this letter.

Clinical Trials Registration: *clinicaltrials.gov* Identifier: NCT01100255

Case report

A 24-year-old woman with DSM-IV OCD (and no other Axis-I disorder) presented in May 2010 for treatment of her obsessions about symmetry/exactness (needing to have objects in the right place or else it doesn't "feel right") and associated repeating/checking compulsions. She spent nearly 8 hours a day managing her OCD symptoms, which interfered with her work and social relationships. She was medically healthy and not on medication due to failing 3 prior SRI trials: fluoxetine 60mg, escitalopram 30mg, clomipramine 200mg (each for over 3 months). Augmentation strategies were unsuccessfully attempted (e.g. she refused a trial of an anti-psychotic due to the possible side effect of weight gain and did not adhere to a trial of cognitive behavioral therapy with exposure and ritual prevention). At baseline, she had severe OCD (Yale-Brown Obsessive Compulsive Scale [YBOCS] = 30)¹² and minimal depressive symptoms (Hamilton Depression Rating Scale = 7).¹³ Her sister has OCD, and her mother has depression. She provided written informed consent after a full explanation of the research procedures and their risks. The institutional review board approved the study.

Following the protocol used in a prior depression study,¹¹ she received two double-blind intravenous infusions over 40 minutes given 1 week apart of saline or 0.5 mg/kg ketamine hydrochloride. An anesthesiologist provided continuous monitoring during the infusion. The patient's symptoms were assessed at baseline, every 10 minutes during the 40 minute infusion (to detect rapid changes in symptoms if they occurred), and at several post-infusion time-points (both on the day of the infusion and up to 1 week later) using the OCD Visual Analogue Scale (OCD-VAS, a modified self-rating scale used previously to detect rapid changes in OCD symptoms;^{14–16} we focused on obsessions, which are more readily assessed rapidly than compulsions). She reported minimal reduction in obsessions during the first infusion (placebo/saline) (Figure 1A), but complete cessation of obsessions during the second infusion (ketamine) (Figure 1B). Obsessions partially re-emerged 40 to 230 minutes post-infusion (Figure 1B), plateauing until post-infusion Day 2; the obsessions did not return to baseline levels until post-infusion Day 7.

During both the saline and ketamine infusion, vital signs remained within normal limits. At all time points, she denied symptoms of mania (Young Mania Rating Scale=0), psychosis (Brief Psychiatric Rating Scale=0) or intoxication (Visual Analogue Scale for Intoxication=0) using standard scales.^{10, 17, 18} During the saline infusion, she reported lightheadedness. During the ketamine infusion, she reported lightheadedness, dry mouth, and feelings of unreality (Clinician-Administered Dissociative States Scale=1)¹⁹ that resolved 5 minutes after the infusion stopped.

This case report suggests that ketamine might have rapid anti-obsessional effects that persist from 1 to 7 days post-infusion, long after the drug has cleared. Limitations include small sample size and the difficulties of blinding due to the psychoactive effects of ketamine. A larger trial is underway to further evaluate ketamine's efficacy, safety, duration, and mechanism of effect. In sum, ketamine may provide a useful tool to study the glutamatergic mechanism implicated in OCD and, if proven effective, may help identify novel drug targets for this disabling illness.

Acknowledgments

Funding support: This investigation was supported a grant from National Institutes of Mental Health (5T32 MH015144-31), the Pisetsky Young Investigator Award, and the Molberger Scholar Award (to Dr. Rodriguez).

James Bender for independent evaluations. Dr. Bender reports no additional financial or other relationships relevant to the subject of this letter.

4) REFERENCES

1. Murray, CJL.; Lopez, AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press; 1996.
2. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. *Biol Psychiatry*. 2005 Sep 1; 58(5):424–428. [PubMed: 15993857]
3. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. *J Clin Psychopharmacol*. 2009 Feb; 29(1):51–55. [PubMed: 19142108]
4. Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial. *Psychopharmacol Bull*. 2009; 42(1):81–93. [PubMed: 19204653]
5. Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. *J Clin Psychopharmacol*. 2010 Feb; 30(1):34–39. [PubMed: 20075645]
6. Rodriguez CI, Bender J Jr, Marcus SM, Snape M, Rynn M, Simpson HB. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. *J Clin Psychiatry*. 2010 Sep; 71(9):1247–1249. [PubMed: 20923629]
7. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. *Psychopharmacology (Berl)*. 2006 Jan; 184(2): 254–256. [PubMed: 16374600]
8. Johnson JW, Kotermanski SE. Mechanism of action of memantine. *Curr Opin Pharmacol*. 2006 Feb; 6(1):61–67. [PubMed: 16368266]
9. Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. *Nature*. 2007 Aug 23; 448(7156):894–900. [PubMed: 17713528]
10. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry*. 2000 Feb 15; 47(4):351–354. [PubMed: 10686270]
11. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry*. 2006 Aug; 63(8):856–864. [PubMed: 16894061]
12. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. *Arch Gen Psychiatry*. 1989 Nov; 46(11):1012–1016. [PubMed: 2510699]
13. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 1960; 23:56–62. [PubMed: 14399272]
14. Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. *Psychopharmacology (Berl)*. 1989; 98(2):275–282. [PubMed: 2502799]
15. Greenberg BD, Benjamin J, Martin JD, et al. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. *Psychopharmacology (Berl)*. 1998 Dec; 140(4):434–444. [PubMed: 9888619]
16. Abrantes AM, Strong DR, Cohn A, et al. Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder. *J Anxiety Disord*. 2009 Oct; 23(7):923–927. [PubMed: 19616916]
17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychology Reports*. 1962; 10:799–812.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA. Young Mania Rating Scale. *The British Journal of Psychiatry*. 1978; 133:429. [PubMed: 728692]
19. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, DSC. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). *J Trauma Stress*. 1998; 11:125–136. [PubMed: 9479681]

Figure 1.

Assessment of obsessions during 40 minute infusion of either saline (A) or ketamine (B) with the OCD Visual Analogue Scale. Safety assessments Brief Psychiatric Rating Scale and Young Mania Scale at 0, 40, 80, 110, 230 minutes and 7 days were all 0. The Clinician Administered Dissociative Scale at 0, 40, 230 and 7 days was 0 at all time points except 40 minutes = 1 (feelings of unreality “things seem a little unreal, but I’m well aware of where I’m at”).